Wistar scientists develop a new, long-lasting antibody treatment, CA9-PMTE, targeting advanced ccRCC using synthetic DNA.
Wistar scientists developed Persistent Multivalent T Cell Engager (CA9-PMTE), a new antibody treatment targeting CA9 for advanced clear cell renal cell carcinoma (ccRCC). This treatment shows promise in pre-clinical models as a potent, long-lasting treatment against ccRCC. The researchers also demonstrated that the therapy could be delivered using synthetic DNA, allowing therapeutic production directly in patients.
June 04, 2024
3 Articles